HC Wainwright Predicts FibroBiologics FY2030 Earnings

FibroBiologics Inc. (NASDAQ:FBLG) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of FibroBiologics in a research report issued on Thursday, February 26th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.62) for the year. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.06.

FBLG has been the topic of several other research reports. D. Boral Capital dropped their price objective on shares of FibroBiologics from $15.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.50.

FibroBiologics Price Performance

NASDAQ:FBLG opened at $0.33 on Friday. FibroBiologics has a one year low of $0.22 and a one year high of $1.53. The company has a fifty day moving average price of $0.29 and a 200 day moving average price of $0.39. The stock has a market cap of $22.21 million, a P/E ratio of -0.78 and a beta of -0.60.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in FBLG. Yorkville Advisors Global LP bought a new position in FibroBiologics during the third quarter worth about $278,000. Landscape Capital Management L.L.C. acquired a new position in shares of FibroBiologics in the 3rd quarter worth approximately $191,000. Geode Capital Management LLC raised its holdings in shares of FibroBiologics by 20.7% in the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after buying an additional 59,813 shares in the last quarter. Cascade Financial Partners LLC lifted its position in shares of FibroBiologics by 11.7% during the 2nd quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after buying an additional 30,500 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in FibroBiologics by 287.3% in the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after buying an additional 171,800 shares in the last quarter.

Insider Activity at FibroBiologics

In other FibroBiologics news, General Counsel Ruben A. Garcia bought 140,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $0.34 per share, for a total transaction of $47,600.00. Following the transaction, the general counsel owned 140,000 shares in the company, valued at approximately $47,600. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 13.00% of the company’s stock.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.